Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts

Publisher's Note: There is a Blood Commentary on this article in this issue.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-10, Vol.136 (17), p.1983-1988
Hauptverfasser:	Perner, Florian, Gadrey, Jayant Y., Xiong, Yijun, Hatton, Charles, Eschle, Benjamin K., Weiss, Andreas, Stauffer, Frédéric, Gaul, Christoph, Tiedt, Ralph, Perry, Jennifer A., Armstrong, Scott A., Krivtsov, Andrei V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Benzimidazoles - pharmacokinetics Benzimidazoles - therapeutic use Drugs, Investigational - pharmacokinetics Drugs, Investigational - therapeutic use Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Histone-Lysine N-Methyltransferase - antagonists & inhibitors Humans Jurkat Cells K562 Cells Letter to Leukemia - drug therapy Leukemia - pathology Mice Treatment Outcome Tumor Cells, Cultured Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Publisher's Note: There is a Blood Commentary on this article in this issue.
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood.2020006113